Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PLEC | Q15149 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6617663 | 0.91 | L3MBTL1 (0.53) | L3MBTL1MAPTNPSR1KDM4EALOX15 | |
| SCHEMBL5657713 | 0.89 | L3MBTL1 (0.46) | L3MBTL1MAPTNPSR1KDM4EALDH1A1 | |
| SCHEMBL3171854 | 0.83 | TAAR1 (0.41) | L3MBTL1MAPTNPSR1KDM4EALOX15 | |
| SCHEMBL3593144 | 0.83 | CA12 (0.54) | KDM4EHTTPOLB | |
| SCHEMBL5660413 | 0.83 | HTR1A (0.59) | L3MBTL1MAPTGAATDP1MAPK1 | |
| SCHEMBL5658385 | 0.83 | CA1 (0.49) | — | |
| Alcohol SCHEMBL11040577 | 0.83 | CA12 (0.50) | KDM4EHTTPOLB | |
| SCHEMBL1960375 | 0.82 | KDM4E (0.46) | L3MBTL1MAPTNPSR1KDM4EALOX15 | |
| SCHEMBL24041895 | 0.82 | HTR1A (0.46) | — | |
| SCHEMBL2345631 | 0.81 | L3MBTL1 (0.61) | L3MBTL1MAPTNPSR1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9701657-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | L3MBTL1 2659/4885MAPT 1965/4885NPSR1 577/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | L3MBTL1 2659/4885MAPT 1965/4885NPSR1 577/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | L3MBTL1 2341/4885MAPT 1584/4885NPSR1 1430/4885 |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | L3MBTL1 972/4885MAPT 2724/4885NPSR1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.